Statens Serum Institut
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
6
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Tuberculosis TB vaccine to prevent reactivation (US 9,074,001) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Tuberculosis TB vaccine to prevent reactivation (US 10,519,202) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis (US 10,641,770) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,026,076 | IP-10 based immunological monitoring In force · From the USPTO record | In force | From the USPTO record | |
| US 8,288,090 | Influenza vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 7,749,520 | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,009 | Use of monomycolyl glycerol (MMG) as an adjuvant In force · From the USPTO record | In force | From the USPTO record | |
| US 10,519,202 | Tuberculosis TB vaccine to prevent reactivation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,074,001 | Tuberculosis TB vaccine to prevent reactivation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,764,024 | Optimized influenza vaccines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,422,348 | Production of a cysteine rich protein In force · From the USPTO record | In force | From the USPTO record | |
| US 9,410,960 | Method of diagnosing galactosemia in neonatal screening In force · From the USPTO record | In force | From the USPTO record | |
| US 10,925,954 | Vaccines against Chlamydia sp. In force (reinstated) · High confidence | In force (reinstated) | High confidence |
Also on record, not counted in the 21: 1 patent in force now held by others · 24 lapsed for an unpaid fee · 18 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 abandoned · 14 no status recorded